Hamlet Biopharma AB (publ) (7ZT)

Overview

Hamlet BioPharma AB (publ), originally known as Hamlet Pharma AB (publ) until its name change in August 2023, is a pioneering entity in the pharmaceutical industry, dedicated explicitly to combating cancer. Founded in 1999 and situated in Lund, Sweden, the company undertakes the illustrious mission of developing drugs for both the treatment and prevention of various cancers. Leveraging the remarkable properties of HAMLET, a tumoricidal protein-lipid complex comprised of two molecules ubiquitously recognized as safe (GRAS) and found in human milk, Hamlet BioPharma AB (publ) targets a broad spectrum of oncology markets. These include, but are not limited to, colon, bladder, and cervix cancers, alongside primary or metastatic brain tumors. A subsidiary of Linnane Pharma AB, Hamlet BioPharma situates itself at the forefront of innovation, pushing the boundaries of conventional cancer treatment methodologies.

Products and Services

• Alpha1H

Developed for the targeted treatment of bladder cancer and brain tumors, Alpha1H symbolizes a monumental stride in oncological therapeutics. This innovative product underlines Hamlet BioPharma AB's commitment to harnessing the therapeutic potentials of HAMLET for addressing some of the most challenging cancer types. By targeting specific cancers, Alpha1H not only promises enhanced efficacy but also a reduction in the adverse effects commonly associated with cancer therapies.

• BAMLET

Another groundbreaking product in Hamlet BioPharma AB's arsenal, BAMLET, is oriented towards the treatment of colon and oral cancer. Embodying the company's versatile approach to cancer treatment, BAMLET utilizes the tumoricidal attributes of HAMLET to target cancer cells effectively. This approach not only signifies the company's innovative capabilities but also demonstrates its commitment to expanding the potential applications of HAMLET in oncology. BAMLET stands as a testament to Hamlet BioPharma AB’s relentless pursuit of excellence in cancer care.